Biofrontera AG Reports 21.6% Rise in First-Half 2025 Sales to EUR 8.8 Million; Net Loss Narrows to EUR 3.7 Million
Biofrontera AG reported a 21.6% increase in first-half 2025 sales to EUR 8.76 million, with a narrowed net loss of EUR 3.69 million. Sales in Germany rose 24.5%, while EBITDA improved to EUR 2.07 million. The company signed a strategic restructuring agreement with Biofrontera Inc., transferring U.S. market assets in exchange for shares and royalties. New sales guidance for 2025 is projected between EUR 17.0 million and EUR 20.0 million.
Biofrontera AG reported its financial results for the first half of 2025, with group sales rising 21.59% to EUR 8.76 million, compared to EUR 7.21 million in the first half of 2024. In Europe, sales increased by 2.6% to EUR 6.25 million, up from EUR 6.09 million in the previous year. Sales in Germany rose 24.5% to EUR 4.42 million, while Spain and the UK recorded increases of 7.0% and 10.8%, reaching EUR 0.99 million and EUR 0.52 million, respectively. EBITDA improved to EUR 2.07 million, compared to a loss of EUR 3.56 million in the first half of 2024. EBIT was EUR 1.64 million, up from a loss of EUR 3.97 million in the year-ago period. The financial result improved to a loss of EUR 0.18 million from a loss of EUR 1.38 million in the first half of 2024, primarily due to a lower impairment on the investment in Biofrontera Inc. Loss after income tax was EUR 3.69 million, compared to EUR 5.34 million in the prior-year period. During the reporting period, Biofrontera AG and Biofrontera Inc. signed a binding agreement on a strategic restructuring of their collaboration. The agreement transferred all assets and liabilities associated with the U.S. market to Biofrontera Inc. in exchange for shares and a new royalty arrangement. Following this restructuring, Biofrontera AG published new guidance on August 1, 2025, with projected sales for 2025 in the range of EUR 17.0 million to EUR 20.0 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera AG published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
